Literature DB >> 12118374

The protective effect of phorbol esters on Fas-mediated apoptosis in T cells. Transcriptional and postranscriptional regulation.

Magali Herrant1, Frédéric Luciano, Agnès Loubat, Patrick Auberger.   

Abstract

Phorbol esters are tumor promoters that bind and activate both conventional and new Protein kinase C (PKC) isoforms. In various circumstances, PKC-dependent signaling pathways can promote cell survival and protect against cell death. This was first analysed in Jurkat T cells where Phorbol Myristate Acetate (PMA) was found to inhibit Fas-mediated apoptosis as judged by DiOC6(3) staining, caspase activation and DNA fragmentation, indicating that PMA exerts its protective effect upstream or at the mitochondrial level in these cells. PMA activated most of the main kinase pathways in T cells such as PKCs, p42/44MAPK, p38MAPK and p90Rsk but not JNK and Akt. A pharmacological approach allowed us to identify that nPKCs are both necessary and likely sufficient to promote T cell survival. Besides this post-transcriptional regulation, nPKCs may also regulate apoptosis at the transcriptional level. cDNA arrays were used to identify a set of genes whose expression was modulated in death versus survival conditions. Following PMA treatment, expression of Mcl-1 and Bcl-x increased while that of c-Myc was significantly reduced. Moreover, survivin expression decreased upon CH11 or PMA treatment. c-Myc, survivin and Bcl-x modulation seems to be regulated at the transcriptional level while decrease in Mcl-1 protein in CH11-treated cells resulted especially from a caspase-dependent proteolysis. Taken together, our data demonstrate that PMA-mediated inhibition of apoptosis is a complex process that is integrated at both the transcriptional and post-transcriptional level and point out to the potential role of Mcl-1, Bcl-x, c-Myc and survivin in this process.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118374     DOI: 10.1038/sj.onc.1205689

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  8 in total

1.  Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.

Authors:  Claire J Chalmers; Kathryn Balmanno; Kathryn Hadfield; Rebecca Ley; Simon J Cook
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

Review 2.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

3.  Identification of an In Vivo MEK/WOX1 Complex as a Master Switch for Apoptosis in T Cell Leukemia.

Authors:  Hsin-Ping Lin; Jean-Yun Chang; Sing-Ru Lin; Ming-Hui Lee; Shenq-Shyang Huang; Li-Jin Hsu; Nan-Shan Chang
Journal:  Genes Cancer       Date:  2011-05

4.  Prosurvival and proapoptotic functions of ERK1/2 activation in murine thymocytes in vitro.

Authors:  Irina S Smirnova; Steve Chang; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2009-10-19       Impact factor: 4.868

5.  BMPR2 expression is suppressed by signaling through the estrogen receptor.

Authors:  Eric D Austin; Rizwan Hamid; Anna R Hemnes; James E Loyd; Tom Blackwell; Chang Yu; John A Phillips Iii; Radhika Gaddipati; Santhi Gladson; Everett Gu; James West; Kirk B Lane
Journal:  Biol Sex Differ       Date:  2012-02-20       Impact factor: 5.027

6.  Constitutive and activation-dependent phosphorylation of lymphocyte phosphatase-associated phosphoprotein (LPAP).

Authors:  Natalia A Kruglova; Tatiana D Meshkova; Arthur T Kopylov; Dmitriy V Mazurov; Alexander V Filatov
Journal:  PLoS One       Date:  2017-08-21       Impact factor: 3.240

7.  Acadesine kills chronic myelogenous leukemia (CML) cells through PKC-dependent induction of autophagic cell death.

Authors:  Guillaume Robert; Issam Ben Sahra; Alexandre Puissant; Pascal Colosetti; Nathalie Belhacene; Pierre Gounon; Paul Hofman; Fréderic Bost; Jill-Patrice Cassuto; Patrick Auberger
Journal:  PLoS One       Date:  2009-11-18       Impact factor: 3.240

8.  BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.

Authors:  Thomas Cluzeau; Guillaume Robert; Nicolas Mounier; Jean Michel Karsenti; Maeva Dufies; Alexandre Puissant; Arnaud Jacquel; Aline Renneville; Claude Preudhomme; Jill-Patrice Cassuto; Sophie Raynaud; Frederic Luciano; Patrick Auberger
Journal:  Oncotarget       Date:  2012-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.